Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Sign Up to like & getrecommendations! Published in 2021 at "Nature"
DOI: 10.1038/s41586-021-03681-2
Abstract: The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against SARS-CoV-2 variants of concern… read more here.
Keywords: wa1 2020; ad26 cov2; antibody; cov variants ... See more keywords